氯沙坦對原發(fā)性高血壓患者纖溶功能的影響-資料下載頁
2025-01-06 12:03本頁面
【正文】 em as an independent primary risk factor[J]. Circulation. 1998,98:2241 2247. KKME專業(yè)醫(yī)學(xué)搜索引擎 ［ 5］ Papakonstantinou E, Roth M, Kokkas B, et al. Losartan inhibits the angiotensin induced modifications on fibrinolysis and matrixdeposition by primary vascular smooth muscle cells [J]. J Cardiovasc Pharmacol, 2022,38:715 728. ［ 6］ Saito M, Kavasski S, Hasbiba T, et al. Effects of losartan, angiotensin Ⅱ receptor antagonist, on the fibrinolytic system in hypertensive patients[J]. Int J Hematol,1999,70:60 61. ［ 7］ Erdem Y, Uealan C, Hasnedaroglu IC, et al. Effects of angiotensin converting enzyme and angiotensin Ⅱ receptor inhibition on impaired fibrinolysis in systemic hypertension[J]. Am J Hypertension,1999,11:1071 1076. ［ 8］李 艷，胡啟均，黃 俊 .氯沙坦對高血壓患者血漿纖溶酶原1活性及內(nèi)皮素水平的影響 [J].中國醫(yī)藥， 2022， 1：22 23. ［ 9］ Koh KK, Chung WJ, Ahn JY, et al. Angiotensin Ⅱ type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type 1 antigen in hypertensive patients: a randomized, doubleblind, placebo controlled study[J]. Atherosclerosis. 2022,177:155160. ［ 10］ Lin TH, Voon WC, Yen HW, et al. Lercanidipine and losartan effects on blood pressure and fibrinolytic parameters[J]. Kaohsiung J Mde Sci, 2022, 22:177 183. KKME專業(yè)醫(yī)學(xué)搜索引擎 可以免費下載論文的瀏覽器 文獻檢索瀏覽器
公司管理相關(guān)推薦
鄂ICP備17016276號-1